Search

Your search keyword '"Alejandro David Bendala Estrada"' showing total 2 results
Start Over Author "Alejandro David Bendala Estrada" Topic macrolides
2 results on '"Alejandro David Bendala Estrada"'

1. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy

Author

Alejandro David Bendala Estrada, Jorge Calderón Parra, Eduardo Fernández Carracedo, Antonio Muiño Míguez, Antonio Ramos Martínez, Elena Muñez Rubio, Manuel Rubio-Rivas, Paloma Agudo, Francisco Arnalich Fernández, Vicente Estrada Perez, María Luisa Taboada Martínez, Anxela Crestelo Vieitez, Paula Maria Pesqueira Fontan, Marta Bustamante, Santiago J. Freire, Isabel Oriol-Bermúdez, Arturo Artero, Julián Olalla Sierra, María Areses Manrique, H. Francisco Javier Carrasco-Sánchez, Vanessa Carolina Vento, Gema María García García, Pablo Cubero-Morais, José-Manuel Casas-Rojo, and Jesús Millán Núñez-Cortés

Subjects
COVID-19, SARS-CoV-2, Antibiotics, Survival, Macrolides, Azithromycin, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Since December 2019, the COVID-19 pandemic has changed the concept of medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital due to SARS-CoV-2 infection. Methods This work analyzes the use and effectiveness of antibiotics in hospitalized patients with COVID-19 based on data from the SEMI-COVID-19 registry, an initiative to generate knowledge about this disease using data from electronic medical records. Our primary endpoint was all-cause in-hospital mortality according to antibiotic use. The secondary endpoint was the effect of macrolides on mortality. Results Of 13,932 patients, antibiotics were used in 12,238. The overall death rate was 20.7% and higher among those taking antibiotics (87.8%). Higher mortality was observed with use of all antibiotics (OR 1.40, 95% CI 1.21–1.62; p

Published
2021
Full Text
View/download PDF

2. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy

Author

Francisco Arnalich Fernández, H Francisco Javier Carrasco-Sánchez, Jesús Millán Núñez-Cortés, Santiago Jesús Freire, Gema María García García, Julián Olalla Sierra, Paloma Agudo, María Luisa Taboada Martínez, José-Manuel Casas-Rojo, Pablo Cubero-Morais, Elena Rubio, Vanessa Carolina Vento, Manuel Rubio-Rivas, Jorge Calderón Parra, Paula Maria Pesqueira Fontan, Antonio Ramos Martínez, Isabel Oriol-Bermúdez, Marta Bustamante, María Areses Manrique, Anxela Crestelo Vieitez, Antonio Muiño Miguez, Alejandro David Bendala Estrada, Arturo Artero, Eduardo Fernández Carracedo, and Vicente Estrada Perez

Subjects
medicine.medical_specialty, Survival, medicine.drug_class, Antibiotics, Antibiòtics, Infectious and parasitic diseases, RC109-216, Disease, Azithromycin, Medical microbiology, Pandemic, Clinical endpoint, medicine, Humans, Intensive care medicine, Supervivència, Pandemics, business.industry, SARS-CoV-2, Medical record, Mortality rate, Research, COVID-19, Anti-Bacterial Agents, COVID-19 Drug Treatment, Infectious Diseases, Macrolides, business, medicine.drug
Abstract

BackgroundSince December 2019, the COVID-19 pandemic has changed the concept of medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital due to SARS-CoV-2 infection.MethodsThis work analyzes the use and effectiveness of antibiotics in hospitalized patients with COVID-19 based on data from the SEMI-COVID-19 registry, an initiative to generate knowledge about this disease using data from electronic medical records. Our primary endpoint was all-cause in-hospital mortality according to antibiotic use. The secondary endpoint was the effect of macrolides on mortality.ResultsOf 13,932 patients, antibiotics were used in 12,238. The overall death rate was 20.7% and higher among those taking antibiotics (87.8%). Higher mortality was observed with use of all antibiotics (OR 1.40, 95% CI 1.21–1.62;p p ConclusionsBacterial co-infection was uncommon among COVID-19 patients, yet use of antibiotics was high. There is insufficient evidence to support widespread use of empiric antibiotics in these patients. Most may not require empiric treatment and if they do, there is promising evidence regarding azithromycin as a potential COVID-19 treatment.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results